Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00842348 · ClinicalTrials.gov registry record · Phase 3
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
A Phase 3 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
NCT00842348 is a Phase 3 study that has completed, run by Ipsen. The registered enrollment target is 89 participants.
The verdict
NCT00842348, a Phase 3 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
Study Summary
The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28 days) and who participated in a previous study, 2-55-52030-726 (NCT00353496).
Interventions
- DRUG lanreotide (Autogel formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00842348
The ClinicalTrials.gov registry entry for NCT00842348 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lanreotide (Autogel formulation) is the first listed.
NCT00842348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00842348 about?
NCT00842348 is a clinical study titled "Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour". The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28 days) and who participated in a previous study, 2-55-52030-726 (NCT0035349...
What is the current status of trial NCT00842348?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 2009-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00842348?
The interventions under investigation include: lanreotide (Autogel formulation) (DRUG).
Who is sponsoring clinical trial NCT00842348?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.